Jeb Keiper

Jeb Keiper is the Chief Executive Officer of Nimbus Therapeutics, a biotechnology company coupling targets selected based on causal human biology with structure-based drug discovery and development. Jeb joined Nimbus in 2014 as Chief Business Officer and became Chief Financial Officer in 2016. He oversaw finance, business development, IP, legal, PR, and operations at Nimbus, prior to being appointed President and Chief Executive Officer of Nimbus in October 2018. Jeb is an independent director on the Boards of Cardurion Pharmaceuticals, a clinical-stage cardiovascular diseases company and Rome Therapeutics, an oncology-focused preclinical biotech company. Prior to Nimbus, Jeb was VP of Business Development at GSK Oncology and spent a decade at GSK in various BD leadership roles. Jeb led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014. Prior to GSK, Jeb was a consultant at McKinsey and worked in BD at TransForm Pharmaceuticals. Jeb began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT; one in Chemistry, two in Chemical Engineering, and an MBA from MIT Sloan.